Twist bioscience corp (TWST)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Revenues

19,297

17,164

15,736

13,600

13,557

11,492

8,407

6,541

6,166

4,313

Operating expenses:
Cost of revenues

13,564

13,792

12,386

11,394

11,789

11,857

9,093

7,503

8,095

7,498

Research and development

10,629

10,297

10,496

9,007

8,907

7,273

6,065

5,268

4,711

4,303

Selling, general and administrative

27,190

26,405

24,423

21,320

19,124

15,259

12,953

11,256

9,978

9,263

Litigation settlement

0

22,500

-

-

-

-

-

-

-

-

Total operating expenses

51,383

72,994

47,305

41,721

39,820

34,389

28,111

24,027

22,784

21,064

Loss from operations

-32,086

-55,830

-31,569

-28,121

-26,263

-22,897

-19,704

-17,486

-16,618

-16,751

Interest income

576

564

789

804

775

664

409

284

148

158

Interest expense

215

248

288

318

340

348

386

337

317

273

Other income (expense), net

18

-87

-2

-227

-21

-15

-45

-14

-43

-19

Loss before income taxes

-31,707

-55,601

-31,070

-27,862

-25,849

-22,596

-19,726

-17,553

-16,830

-16,885

Provision for income taxes

61

37

111

54

84

43

76

71

43

52

Net loss attributable to common stockholders

-31,768

-55,638

-31,181

-27,916

-25,933

-22,639

-19,802

-17,624

-16,873

-16,937

Other comprehensive loss:
Change in unrealized gain on investments

12

16

33

3

20

-7

-

-

1

-1

Foreign currency translation adjustment

11

-7

31

250

-180

-56

19

14

11

10

Comprehensive loss

-31,745

-55,629

-31,117

-27,663

-26,093

-22,702

-19,783

-17,610

-16,861

-16,928

Net loss per share attributable to common stockholders—basic and diluted

-0.85

-1.69

-0.89

-0.92

-0.93

-1.18

-6.59

-6.18

-6.32

-6.42

Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted

37,163

32,976

79,510,146

30,290,150

27,891

19,187

3,013,819

2,849,544

2,669,541

2,638,068